Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have been given a consensus rating of “Moderate Buy” by the twelve analysts that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, ten have given a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $10.9091.

TSHA has been the subject of a number of research analyst reports. The Goldman Sachs Group set a $11.00 target price on Taysha Gene Therapies in a research report on Thursday, December 4th. Citizens Jmp set a $8.00 price objective on Taysha Gene Therapies in a report on Wednesday, November 5th. Wall Street Zen lowered Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Monday, December 29th. Finally, Wells Fargo & Company boosted their price target on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday, January 5th.

Insider Transactions at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 26,918 shares of the stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $4.61, for a total value of $124,091.98. Following the completion of the sale, the insider directly owned 1,317,389 shares of the company’s stock, valued at $6,073,163.29. This represents a 2.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Sean P. Nolan sold 41,312 shares of Taysha Gene Therapies stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $4.61, for a total value of $190,448.32. Following the transaction, the chief executive officer directly owned 2,908,257 shares in the company, valued at approximately $13,407,064.77. The trade was a 1.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 858,670 shares of company stock valued at $3,995,000 over the last three months. Corporate insiders own 3.78% of the company’s stock.

Hedge Funds Weigh In On Taysha Gene Therapies

Large investors have recently bought and sold shares of the stock. Intech Investment Management LLC grew its stake in shares of Taysha Gene Therapies by 3.6% in the 4th quarter. Intech Investment Management LLC now owns 71,069 shares of the company’s stock worth $391,000 after acquiring an additional 2,443 shares in the last quarter. Chicago Partners Investment Group LLC lifted its position in shares of Taysha Gene Therapies by 1.5% during the fourth quarter. Chicago Partners Investment Group LLC now owns 166,541 shares of the company’s stock valued at $916,000 after purchasing an additional 2,504 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Taysha Gene Therapies by 26.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,311 shares of the company’s stock worth $73,000 after purchasing an additional 2,765 shares during the last quarter. Virtus Investment Advisers LLC grew its position in Taysha Gene Therapies by 7.0% in the 4th quarter. Virtus Investment Advisers LLC now owns 45,946 shares of the company’s stock worth $253,000 after purchasing an additional 3,008 shares in the last quarter. Finally, Xponance Inc. increased its stake in Taysha Gene Therapies by 29.1% in the 3rd quarter. Xponance Inc. now owns 16,575 shares of the company’s stock valued at $54,000 after buying an additional 3,738 shares during the last quarter. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Trading Down 0.9%

NASDAQ:TSHA opened at $4.53 on Tuesday. Taysha Gene Therapies has a 12 month low of $1.05 and a 12 month high of $6.02. The company has a current ratio of 10.48, a quick ratio of 10.48 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $1.24 billion, a price-to-earnings ratio of -13.73 and a beta of 1.01. The firm has a fifty day simple moving average of $4.92 and a two-hundred day simple moving average of $4.39.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.